Roll over image to zoom in
Proviron – Golden Dragon
£39.00
Proviron For Sale UK & EU
Proviron, also known as Mesterolone, plays a significant role in post-cycle therapy (PCT) for bodybuilders. Its ability to increase testosterone levels by inhibiting estrogen conversion helps to restore hormonal balance after a steroid cycle. Typically used in dosages of 25-50mg daily during PCT, it aids in preventing estrogen-related side effects while promoting the recovery of natural testosterone production. However, users should exercise caution and follow recommended protocols to avoid adverse effects.
Increase in Androgenicity
- Enhanced Muscle Hardness: Proviron can increase androgenicity in a steroid cycle, helping create a harder and denser muscle appearance.
- Reduced Aromatization: It helps reduce the effects of aromatization (conversion of testosterone to estrogen), minimizing the risk of estrogenic side effects such as gynecomastia.
Improved Libido
- Many users report an increase in libido and sexual function due to its androgenic effect, which raises levels of free testosterone.
Reduction of SHBG
- Proviron can bind to sex hormone-binding globulin (SHBG), which increases the amount of free testosterone in the body, potentially amplifying the effects of other anabolic steroids.
Enhanced Muscle Definition
- By not converting to estrogen, Proviron helps prevent water retention, promoting a more defined and dry muscular appearance.
Aid in Cutting Cycles
- It is often used in cutting cycles to help preserve muscle mass while reducing body fat, improving overall muscle quality.
How Proviron is Used
- Dosage: The typical dosage of Proviron ranges from 25 to 100 mg per day. The specific dose may depend on the user’s experience level and personal goals.
- Cycle: Proviron can be used in both bulking and cutting cycles but is more commonly used in cutting cycles due to its effects on muscle definition.
- Duration: It is generally used for periods of 6 to 12 weeks, depending on cycle needs and objectives.
Reviews
There are no reviews yet.